NCI Extends Contract with Geneart for Gene Production
Follow-up order totals $1.9M for the synthesis of another 200 genes.!--h2>
Geneart has agreed to continue the production of genes for the NCI under a contract worth $1.9 million. The company has already produced more than 3,500 genes at a cost of $3.5 million. The new deal covers the synthesis of another 200 highly genes.
This gene collection for the NCI complements the NIH Mammalian Gene Collection (MGC) Program . This comprehensive collection of human and mouse genes represents a significant resource for basic research as well as for clinical R&D.
The 3,500 genes so far synthesized by Geneart include a large number of highly complex sequences, which could not be isolated with classical methods of biotechnology in the course of the MGC project between 2002 and 2006, according to the firm. A major proportion of genes in this group showed a high number of repetitive DNA sequence elements or was toxic for the production host E. coli. Since then, Geneart says that it has advanced its existing technologies and established new production techniques so that it can now efficiently synthesize this large number of genes in a high-throughput manner.